IBT’s current pipeline includes two development programs of live bacterial therapies intended for neonatology: IBP-9414 for the prevention of necrotizing enterocolitis (NEC) and IBP-1016 for the treatment of gastroschisis.
IBT’s current lead drug candidate is IBP-9414, developed to prevent NEC in premature infants. IBP-9414 contains the active substance Lactobacillus reuteri, a human bacterial strain naturally present in breast milk. Read more about the Safety and Tolerability study in the Hot Topics presentation.
IBT has an additional project in its portfolio, a second rare disease program, IBP-1016, for the treatment of an unmet medical need in gastroschisis, a severe disease in infants.
By developing these drugs, IBT has the potential to fulfil unmet needs for diseases where there are currently no prevention or treatment therapies available.